


Application No.: NEW APPLICATION

IN THE CLAIMS

The status of each claim is listed below.

Claims 1-81: Canceled.

82. (New) A compound represented by formula (I):




wherein

X is hydrogen, halogen, trifluoromethyl, lower alkyl, unsubstituted or substituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, lower alkyl-sulfonyl, or phenyl-lower alkyl-sulfonyl;


Y is hydrogen, hydroxyl, mercapto, lower alkoxy, lower alkyl-thio, halogen, lower alkyl, unsubstituted or substituted mononuclear aryl, or -N(R<sup>2</sup>)<sub>2</sub>;

R<sup>1</sup> is hydrogen or lower alkyl;

each R<sup>2</sup> is, independently, -R<sup>7</sup>, -(CH<sub>2</sub>)<sub>m</sub>-OR<sup>8</sup>, -(CH<sub>2</sub>)<sub>m</sub>-NR<sup>7</sup>R<sup>10</sup>, -(CH<sub>2</sub>)<sub>n</sub>(CHOR<sup>8</sup>)(CHOR<sup>8</sup>)<sub>n</sub>-CH<sub>2</sub>OR<sup>8</sup>, -(CH<sub>2</sub>CH<sub>2</sub>O)<sub>m</sub>-R<sup>8</sup>, -(CH<sub>2</sub>CH<sub>2</sub>O)<sub>m</sub>-CH<sub>2</sub>CH<sub>2</sub>NR<sup>7</sup>R<sup>10</sup>, -(CH<sub>2</sub>)<sub>n</sub>-C(=O)NR<sup>7</sup>R<sup>10</sup>, -(CH<sub>2</sub>)<sub>n</sub>-Z<sub>g</sub>-R<sup>7</sup>, -(CH<sub>2</sub>)<sub>m</sub>-NR<sup>10</sup>-CH<sub>2</sub>(CHOR<sup>8</sup>)(CHOR<sup>8</sup>)<sub>n</sub>-CH<sub>2</sub>OR<sup>8</sup>, -(CH<sub>2</sub>)<sub>n</sub>-CO<sub>2</sub>R<sup>7</sup>, or




$\text{R}^3$  and  $\text{R}^4$  are each, independently, hydrogen, a group represented by formula (A), lower alkyl, hydroxy lower alkyl, phenyl, phenyl-lower alkyl, (halophenyl)-lower alkyl, lower-(alkylphenylalkyl), lower alkoxyphenyl)-lower alkyl, naphthyl-lower alkyl, or pyridyl-lower alkyl, with the proviso that at least one of  $\text{R}^3$  and  $\text{R}^4$  is a group represented by formula (A):



wherein

each  $\text{R}^L$  is, independently,  $-\text{R}^7$ ,  $-(\text{CH}_2)_n-\text{OR}^8$ ,  $-\text{O}-(\text{CH}_2)_m-\text{OR}^8$ ,  $-(\text{CH}_2)_n-\text{NR}^7\text{R}^{10}$ ,  $-\text{O}-(\text{CH}_2)_m-\text{NR}^7\text{R}^{10}$ ,  $-(\text{CH}_2)_n(\text{CHOR}^8)(\text{CHOR}^8)_n-\text{CH}_2\text{OR}^8$ ,  $-\text{O}-(\text{CH}_2)_m(\text{CHOR}^8)(\text{CHOR}^8)_n-\text{CH}_2\text{OR}^8$ ,  $-(\text{CH}_2\text{CH}_2\text{O})_m-\text{R}^8$ ,  $-\text{O}-(\text{CH}_2\text{CH}_2\text{O})_m-\text{R}^8$ ,  $-(\text{CH}_2\text{CH}_2\text{O})_m-\text{CH}_2\text{CH}_2\text{NR}^7\text{R}^{10}$ ,  $-\text{O}-(\text{CH}_2\text{CH}_2\text{O})_m-\text{CH}_2\text{CH}_2\text{NR}^7\text{R}^{10}$ ,  $-(\text{CH}_2)_n-\text{C}(=\text{O})\text{NR}^7\text{R}^{10}$ ,  $-\text{O}-(\text{CH}_2)_m-\text{C}(=\text{O})\text{NR}^7\text{R}^{10}$ ,  $-(\text{CH}_2)_n-(\text{Z})_g-\text{R}^7$ ,  $-\text{O}-(\text{CH}_2)_m-(\text{Z})_g-\text{R}^7$ ,  $-(\text{CH}_2)_n-\text{NR}^{10}-\text{CH}_2(\text{CHOR}^8)(\text{CHOR}^8)_n-\text{CH}_2\text{OR}^8$ ,  $-\text{O}-(\text{CH}_2)_m-\text{NR}^{10}-\text{CH}_2(\text{CHOR}^8)(\text{CHOR}^8)_n-\text{CH}_2\text{OR}^8$ ,  $-(\text{CH}_2)_n-\text{CO}_2\text{R}^7$ ,  $-\text{O}-(\text{CH}_2)_m-\text{CO}_2\text{R}^7$ ,  $-\text{OSO}_3\text{H}$ ,  $-\text{O-glucuronide}$ ,  $-\text{O-glucose}$ , or

Application No.: NEW APPLICATION



each x is, independently, O, NR<sup>7</sup>, C=O, CHOH, C=N-R<sup>6</sup>, or represents a single bond;

each o is, independently, an integer from 0 to 10;

each p is, independently, an integer from 0 to 10;

with the proviso that (a) the sum of o and p in each contiguous chain is

from 1 to 10 when x is O, NR<sup>7</sup>, C=O, or C=N-R<sup>6</sup> or (b) that the sum of o and p

in each contiguous chain is from 4 to 10 when x represents a single bond;

each R<sup>6</sup> is, independently, -R<sup>7</sup>, -OH, -OR<sup>11</sup>, -N(R<sup>7</sup>)<sub>2</sub>, -(CH<sub>2</sub>)<sub>m</sub>-OR<sup>8</sup>,

-O-(CH<sub>2</sub>)<sub>m</sub>-OR<sup>8</sup>, -(CH<sub>2</sub>)<sub>n</sub>-NR<sup>7</sup>R<sup>10</sup>, -O-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>7</sup>R<sup>10</sup>,

-(CH<sub>2</sub>)<sub>n</sub>(CHOR<sup>8</sup>)(CHOR<sup>8</sup>)<sub>n</sub>-CH<sub>2</sub>OR<sup>8</sup>, -O-(CH<sub>2</sub>)<sub>m</sub>(CHOR<sup>8</sup>)(CHOR<sup>8</sup>)<sub>n</sub>-CH<sub>2</sub>OR<sup>8</sup>,

-(CH<sub>2</sub>CH<sub>2</sub>O)<sub>m</sub>-R<sup>8</sup>, -O-(CH<sub>2</sub>CH<sub>2</sub>O)<sub>m</sub>-R<sup>8</sup>, -(CH<sub>2</sub>CH<sub>2</sub>O)<sub>m</sub>-CH<sub>2</sub>CH<sub>2</sub>NR<sup>7</sup>R<sup>10</sup>,


-O-(CH<sub>2</sub>CH<sub>2</sub>O)<sub>m</sub>-CH<sub>2</sub>CH<sub>2</sub>NR<sup>7</sup>R<sup>10</sup>, -(CH<sub>2</sub>)<sub>n</sub>-C(=O)NR<sup>7</sup>R<sup>10</sup>,

-O-(CH<sub>2</sub>)<sub>m</sub>-C(=O)NR<sup>7</sup>R<sup>10</sup>, -(CH<sub>2</sub>)<sub>n</sub>-(Z)<sub>g</sub>-R<sup>7</sup>, -O-(CH<sub>2</sub>)<sub>m</sub>-(Z)<sub>g</sub>-R<sup>7</sup>,

-(CH<sub>2</sub>)<sub>n</sub>-NR<sup>10</sup>-CH<sub>2</sub>(CHOR<sup>8</sup>)(CHOR<sup>8</sup>)<sub>n</sub>-CH<sub>2</sub>OR<sup>8</sup>,

-O-(CH<sub>2</sub>)<sub>m</sub>-NR<sup>10</sup>-CH<sub>2</sub>(CHOR<sup>8</sup>)(CHOR<sup>8</sup>)<sub>n</sub>-CH<sub>2</sub>OR<sup>8</sup>,

-(CH<sub>2</sub>)<sub>n</sub>-CO<sub>2</sub>R<sup>7</sup>, -O-(CH<sub>2</sub>)<sub>m</sub>-CO<sub>2</sub>R<sup>7</sup>, -OSO<sub>3</sub>H, -O-glucuronide, -O-glucose,




Application No.: NEW APPLICATION

wherein when two  $R^6$  are  $-OR^{11}$  and are located adjacent to each other on a phenyl ring, the alkyl moieties of the two  $R^6$  may be bonded together to form a methylenedioxy group;

each  $R^7$  is, independently, hydrogen or lower alkyl;

each  $R^8$  is, independently, hydrogen, lower alkyl,  $-C(=O)-R^{11}$ , glucuronide, 2-tetrahydropyranyl, or



each  $R^9$  is, independently,  $-CO_2R^7$ ,  $-CON(R^7)_2$ ,  $-SO_2CH_3$ , or  $-C(=O)R^7$ ;

each  $R^{10}$  is, independently,  $-H$ ,  $-SO_2CH_3$ ,  $-CO_2R^7$ ,  $-C(=O)NR^7R^9$ ,

$-C(=O)R^7$ , or  $-CH_2-(CHOH)_n-CH_2OH$ ;

each  $Z$  is, independently,  $CHOH$ ,  $C(=O)$ ,  $CHNR^7R^{10}$ ,  $C=NR^{10}$ , or  $NR^{10}$ ;

each  $R^{11}$  is, independently, lower alkyl;

each  $g$  is, independently, an integer from 1 to 6;

each  $m$  is, independently, an integer from 1 to 7;

each  $n$  is, independently, an integer from 0 to 7;

each  $Q$  is, independently,  $C-R^5$ ,  $C-R^6$ , or a nitrogen atom, wherein three  $Q$  in a ring are nitrogen atoms;

or a pharmaceutically acceptable salt thereof, and

Application No.: NEW APPLICATION

inclusive of all enantiomers, diastereomers, and racemic mixtures thereof.

83. (New) The compound of Claim 82, wherein Y is  $\text{-NH}_2$ .

84. (New) The compound of Claim 83, wherein  $\text{R}^2$  is hydrogen.

85. (New) The compound of Claim 84, wherein  $\text{R}^1$  is hydrogen.

86. (New) The compound of Claim 85, wherein X is chlorine.

87. (New) The compound of Claim 86, wherein  $\text{R}^3$  is hydrogen.

88. (New) The compound of Claim 87, wherein each  $\text{R}^L$  is hydrogen.

89. (New) The compound of Claim 88, wherein o is 4.

90. (New) The compound of Claim 89, wherein p is 0.

91. (New) The compound of Claim 90, wherein x represents a single bond.

92. (New) The compound of Claim 91, wherein each  $\text{R}^6$  is hydrogen.

93. (New) The compound of Claim 92, wherein

Application No.: NEW APPLICATION

X is halogen;

Y is  $-N(R^7)_2$ ;

$R^1$  is hydrogen or  $C_1$ - $C_3$  alkyl;

$R^2$  is  $-R^7$ ,  $-(CH_2)_m-OR^7$ , or  $-(CH_2)_n-CO_2R^7$ ;

$R^3$  is a group represented by formula (A); and

$R^4$  is hydrogen, a group represented by formula (A), or lower alkyl.

94. (New) The compound of Claim 93, wherein

X is chloro or bromo;

Y is  $-N(R^7)_2$ ;

$R^2$  is hydrogen or  $C_1$ - $C_3$  alkyl;

at most three  $R^6$  are other than hydrogen as defined above; and

at most three  $R^L$  are other than hydrogen as defined above.

95. (New) The compound of Claim 94, wherein Y is  $-NH_2$ .

96. (New) The compound of Claim 95, wherein

$R^4$  is hydrogen;

at most one  $R^L$  is other than hydrogen as defined above; and

at most two  $R^6$  are other than hydrogen as defined above.

97. (New) The compound of Claim 96, wherein x is O,  $NR^7$ ,  $C=O$ ,  $CHOH$ , or  $C=N-$   
(

$R^6$ .

Application No.: NEW APPLICATION

98. (New) The compound of Claim 96, wherein x represents a single bond.

99. (New) The compound of Claim 82, wherein x is O,  $\text{NR}^7$ ,  $\text{C}=\text{O}$ ,  $\text{CHOH}$ , or  $\text{C}=\text{N}-\text{R}^6$ .

100. (New) The compound of Claim 82, wherein x represents a single bond.

101. (New) The compound of Claim 82, wherein each  $\text{R}^6$  is hydrogen.

102. (New) The compound of Claim 82, wherein at most two  $\text{R}^6$  are other than hydrogen as defined in Claim 82.

103. (New) The compound of Claim 82, wherein one  $\text{R}^6$  is other than hydrogen as defined in Claim 82.

104. (New) The compound of Claim 82, wherein one  $\text{R}^6$  is  $-\text{OH}$ .

105. (New) The compound of Claim 82, wherein each  $\text{R}^L$  is hydrogen.

106. (New) The compound of Claim 82, wherein at most two  $\text{R}^L$  are other than hydrogen as defined in Claim 82.

Application No.: NEW APPLICATION

107. (New) The compound of Claim 82, wherein one  $R^L$  is other than hydrogen as defined in Claim 82.

108. (New) The compound of Claim 82, wherein x represents a single bond and the sum of o and p is 4 to 6.

109. (New) The compound of Claim 82, which is in the form of a pharmaceutically acceptable salt.

110. (New) The compound of Claim 82, which is in the form of a hydrochloride salt.

111. (New) The compound of Claim 82, which is in the form of a mesylate salt.

112. (New) A pharmaceutical composition, comprising the compound of Claim 82 and a pharmaceutically acceptable carrier.

113. (New) A composition, comprising:  
the compound of Claim 82; and  
a P2Y2 inhibitor.

114. (New) A composition, comprising:  
the compound of Claim 82; and  
a bronchodilator.



Application No.: NEW APPLICATION

115. (New) A method of blocking sodium channels, comprising contacting sodium channels with an effective amount of the compound of Claim 82.

Application No.: NEW APPLICATION

SUPPORT FOR THE AMENDMENTS

The specification has been amended to change the Abstract and to insert continuing application data.

Newly-added Claims 82-115 are supported by the specification at pages 4-52 and original Claims 1-81.

No new matter is believed to have been added to this application by the amendments submitted above.